IXICO (AIM:IXI) has won two contracts totalling £1.3 million over two years with a global diagnostics and life sciences company and a leading global pharmaceutical company to deliver PET imaging analytics and expanded trial analysis respectively.
The Alzheimer's work will supply amyloid PET imaging analytics to validate a new blood-based AD test aimed at supporting FDA regulatory clearance, and the Phase 2 extension adds three new analysis approaches to an existing HD study, with the £1.3 million value covering delivery across the two-year term, IXICO being a neuroscience imaging and biomarker analytics specialist.
Services will be delivered via IXICO's AI-driven imaging platform, processing global trial data to translate scans into quantitative biomarkers for regulatory and clinical endpoints.
"They hit three key components of our growth plan: deepening impact in broader CNS areas such as Alzheimer's, maintaining leadership in rare neurodegenerative diseases like Huntington's, and moving into later‑stage clinical development work," Bram Goorden, Chief Executive Officer.
